Home » Media Center » News » Gornitzky is representing the public biomedical company, Bonus BioGroup Ltd., in a motion to modify the terms of option warrants.
February 24, 2019
Gornitzky is representing the public biomedical company, Bonus BioGroup Ltd., in a motion to modify the terms of option warrants.
Gornitzky is representing the public biomedical company, Bonus BioGroup Ltd., in a motion to modify the terms of option warrants, pursuant to Section 350 of the Companies Law.
In the motion, it was requested, among other things, to determine a “restriction period” during which time the possibility of exercising the shares would not be allowed, notwithstanding the vesting of the option warrants. Even though the transaction was contingent upon the approval of a “trilateral mechanism” in accordance with Section 275 of the Companies Law (in view of the holding of part of the option warrants by the controlling shareholder), the Court allowed the Company’s motion to shorten the count of the number of days for the convening of the meetings.
On February 12, 2019, the meetings approved the arrangement, and on February 13, 2019, a judgment was handed down pursuant to which the aforesaid arrangement was approved.
Bonus BioGroup Ltd is represented by Partner Maya Sabari.
Gornitzky is representing the public biomedical company, Bonus BioGroup Ltd., in a motion to modify the terms of option warrants, pursuant to Section 350 of the Companies Law.
In the motion, it was requested, among other things, to determine a “restriction period” during which time the possibility of exercising the shares would not be allowed, notwithstanding the vesting of the option warrants. Even though the transaction was contingent upon the approval of a “trilateral mechanism” in accordance with Section 275 of the Companies Law (in view of the holding of part of the option warrants by the controlling shareholder), the Court allowed the Company’s motion to shorten the count of the number of days for the convening of the meetings.
On February 12, 2019, the meetings approved the arrangement, and on February 13, 2019, a judgment was handed down pursuant to which the aforesaid arrangement was approved.
Bonus BioGroup Ltd is represented by Partner Maya Sabari.